🇺🇸 FDA
Patent

US 11191843

Multi-arm targeting anti-cancer conjugate

granted A61KA61K31/4745A61K47/60

Quick answer

US patent 11191843 (Multi-arm targeting anti-cancer conjugate) held by BrightGene Bio-Medical Technology Co., Ltd. expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BrightGene Bio-Medical Technology Co., Ltd.
Grant date
Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/4745, A61K47/60, A61K47/64, A61K47/65